JP2015514707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514707A5 JP2015514707A5 JP2015503301A JP2015503301A JP2015514707A5 JP 2015514707 A5 JP2015514707 A5 JP 2015514707A5 JP 2015503301 A JP2015503301 A JP 2015503301A JP 2015503301 A JP2015503301 A JP 2015503301A JP 2015514707 A5 JP2015514707 A5 JP 2015514707A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 198
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 claims description 104
- 239000012634 fragment Substances 0.000 claims description 90
- 239000000427 antigen Substances 0.000 claims description 89
- 102000036639 antigens Human genes 0.000 claims description 89
- 108091007433 antigens Proteins 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 33
- 239000012472 biological sample Substances 0.000 claims description 28
- 239000013074 reference sample Substances 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 17
- 206010003445 Ascites Diseases 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000031864 metaphase Effects 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- -1 chromophore label Chemical compound 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 description 50
- 108091033319 polynucleotide Proteins 0.000 description 50
- 239000002157 polynucleotide Substances 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 26
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000003040 circulating cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618235P | 2012-03-30 | 2012-03-30 | |
| US61/618,235 | 2012-03-30 | ||
| PCT/US2013/031398 WO2013148250A1 (en) | 2012-03-30 | 2013-03-14 | Tem-1 diagnostic antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018016761A Division JP6591580B2 (ja) | 2012-03-30 | 2018-02-01 | Ｔｅｍ−１診断用抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514707A JP2015514707A (ja) | 2015-05-21 |
| JP2015514707A5 true JP2015514707A5 (enExample) | 2016-03-24 |
| JP6285414B2 JP6285414B2 (ja) | 2018-02-28 |
Family
ID=47998546
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503301A Active JP6285414B2 (ja) | 2012-03-30 | 2013-03-14 | Ｔｅｍ−１診断用抗体 |
| JP2018016761A Active JP6591580B2 (ja) | 2012-03-30 | 2018-02-01 | Ｔｅｍ−１診断用抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018016761A Active JP6591580B2 (ja) | 2012-03-30 | 2018-02-01 | Ｔｅｍ−１診断用抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9139656B2 (enExample) |
| EP (2) | EP3543258B1 (enExample) |
| JP (2) | JP6285414B2 (enExample) |
| AU (2) | AU2013240281B2 (enExample) |
| CA (1) | CA2868989C (enExample) |
| WO (1) | WO2013148250A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013240281B2 (en) * | 2012-03-30 | 2017-12-21 | Eisai R&D Management Co., Ltd. | TEM-1 diagnostic antibodies |
| CA2938152A1 (en) * | 2014-02-10 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antibodies that bind to human tau and assay for quantifying human tau using the antibodies |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| LT3515938T (lt) * | 2016-09-21 | 2025-05-12 | Cstone Pharmaceuticals | Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1) |
| WO2020205576A1 (en) * | 2019-03-29 | 2020-10-08 | Celldex Therapeutics, Inc. | Anti-axl antibodies and methods of use thereof |
| WO2020243455A1 (en) * | 2019-05-31 | 2020-12-03 | Ludwig Institute For Cancer Research Ltd | Anti-tem1 antibodies and antigen-binding portions thereof |
| WO2022192358A1 (en) * | 2021-03-10 | 2022-09-15 | Ludwig Institute For Cancer Research Ltd | Anti-tem1 antibodies and antigen-binding portions thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342757A (en) * | 1992-11-13 | 1994-08-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof |
| WO2006017759A2 (en) * | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
| CA2682726C (en) | 2007-04-05 | 2017-05-09 | Morphotek, Inc. | Methods for inhibiting the binding of endosialin to ligands |
| WO2010118203A2 (en) | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Endosialin binding molecules |
| AU2013240281B2 (en) * | 2012-03-30 | 2017-12-21 | Eisai R&D Management Co., Ltd. | TEM-1 diagnostic antibodies |
-
2013
- 2013-03-14 AU AU2013240281A patent/AU2013240281B2/en active Active
- 2013-03-14 CA CA2868989A patent/CA2868989C/en active Active
- 2013-03-14 US US13/804,730 patent/US9139656B2/en active Active
- 2013-03-14 EP EP19169560.0A patent/EP3543258B1/en active Active
- 2013-03-14 JP JP2015503301A patent/JP6285414B2/ja active Active
- 2013-03-14 WO PCT/US2013/031398 patent/WO2013148250A1/en not_active Ceased
- 2013-03-14 EP EP13712651.2A patent/EP2831114B1/en active Active
-
2015
- 2015-08-12 US US14/824,471 patent/US9771429B2/en active Active
-
2017
- 2017-08-23 US US15/684,611 patent/US10662251B2/en active Active
-
2018
- 2018-01-22 AU AU2018200487A patent/AU2018200487B2/en active Active
- 2018-02-01 JP JP2018016761A patent/JP6591580B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524744A5 (enExample) | ||
| HRP20180353T1 (hr) | Protutijela protiv folatnog receptora alfa i njihova upotreba | |
| US20200200753A1 (en) | Methods and kits for detecting prostate cancer biomarkers | |
| JP2015514707A5 (enExample) | ||
| JP6075881B2 (ja) | 乳癌のバイオマーカー | |
| JP2020510409A5 (enExample) | ||
| JP2016500659A5 (enExample) | ||
| RU2015132142A (ru) | Композиции и способы для диагностики и лечения опухоли | |
| JP2016516008A5 (enExample) | ||
| US11719697B2 (en) | Immunoassay and antibodies for the detection of chromogranin A | |
| JP2017133831A (ja) | 大腸がんの転移検出方法 | |
| WO2011010969A1 (en) | Cancer biomarker and the use thereof | |
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| RU2017114626A (ru) | Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике | |
| BR112019020413A2 (pt) | composições e métodos para detectar câncer de próstata | |
| WO2013106913A1 (en) | Biomarkers for breast cancer prognosis and treatment | |
| JP2022031783A (ja) | ＡＰＰ６６９－ｘのＮ末端を特異的に認識する抗体、及び免疫測定法 | |
| CN110412274B (zh) | C6orf106自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| CN104781672A (zh) | 预测女性对象患癌症风险或诊断其癌症的方法 | |
| JP4560314B2 (ja) | 中性アミノ酸トランスポーターによる癌の検出法、及びそのためのキット | |
| CN105474016B (zh) | Augurin免疫试验 | |
| JP7207517B2 (ja) | Ａｐｐ６６９－７１１の測定方法、及び測定用キット | |
| CN110632313B (zh) | Cdpf1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
| JP2012504408A5 (enExample) | ||
| CN108776215A (zh) | 系统性硬化症诊断及pah预测的生物标志物 |